Correspondence 0001493152-26-021527 from Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc.
Date: May 6, 2026 · CIK: 0001716166 · Accession: 0001493152-26-021527
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293492
Letter
Vivos Therapeutics, Inc.
Southpark Plaza, Suite 210
Littleton, Colorado 80120
May 6, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Vivos Therapeutics Inc.
Registration Statement on Form S-3
Filed February 17, 2026
File No. 333-293492
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. ET on Friday, May 8, 2026, or as soon as thereafter practicable.
Very truly yours,
/s/
R. Kirk Huntsman
Show Raw Text
CORRESP 1 filename1.htm Vivos Therapeutics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 May 6, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vivos Therapeutics Inc. Registration Statement on Form S-3 Filed February 17, 2026 File No. 333-293492 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Vivos Therapeutics, Inc. hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. ET on Friday, May 8, 2026, or as soon as thereafter practicable. Very truly yours, /s/ R. Kirk Huntsman R. Kirk Huntsman Chief Executive Officer cc: Ellenoff Grossman & Schole LLP